FDA Withdraws Pending CBD Enforcement Proposal
The White House has also frozen the PMTA rules pending review
U.S. drug regulators have withdrawn their proposal to regulate over-the-counter CBD, handing the industry another setback after years of delay from the Food and Drug Administration.
The proposal in question appears to be on pause because of the changing administration. The delay was widely anticipated but still frustrating for CBD operators awaiting the rules.
The FDA sent the proposal to the White House Office of Management and Budget last July, a final stop before new regulations go public.
But the FDA withdrew its CBD proposal last Thursday, a day after President Joe Biden was inaugurated. The withdrawal came hours after the Biden administration issued a memo to all federal agencies telling them to withdraw pending rules, such as the FDA’s CBD guidance.
To Read The Rest Of This Article On Hemp Industry Daily, Click Here
